Search Cancer Clinical Trials

Search our clinical trials database by disease type, trial number, location or phase. Must press "Go" to activate search.  

GTX 1512   |   12-449
A Phase III, randomized, double-blind, placebo-controlled study of the effect of GTx-024 on Muscle Wasting in patients with Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy.

North Coast Cancer
Phase 3

Contact Information
Cancer Answer Line


8:00 am - 4:30 pm, Monday - Friday

  1. Primary Objectives
    • To assess the efficacy of GTx-024 on physical function
    • To assess the efficacy of GTx-024 on total LBM (overall LBM)
  2. Secondary Objectives
    • To assess the durability of effect of GTx-024 on physical function
    • To assess the durability of effect of GTx-024 on total LBM
    • To assess the change from baseline in physical function in the GTx-024 treatment group compared to placebo
    • To assess the change from baseline in total LBM in the GTx-024 treatment group compared to placebo
  3. Secondary Program Objective
    • To assess the effect of GTx-024 on overall survival (superiority) (pooled data from Protocols G300504 and G300505)
  4. Tertiary Objectives
    • To assess the effect of GTx-024 on healthcare resource utilization
    • To assess the effect of GTx-024 on adherence to chemotherapy treatment plan (i.e. dose intensity)
    • To assess the efficacy of GTx-024 on total body weight
    • To assess the effect of GTx-024 on quality of life as measured by each of the following instruments: FAACT-12, FACIT Fatigue Scale, PROMIS Physical Functioning Short Form 10a, PROMIS Emotional Distress-Depression Short Form 8b, and EQ-5D-5L
    • To assess the minimal clinically meaningful efficacy of GTx-024 on physical function
    • To assess the effect of GTx-024 on tolerance to chemotherapy

Inclusion Criteria
  1. Give voluntary, signed informed consent in accordance with institutional policies
  2. Be non-obese as defined as body mass index (BMI) ≤ 32 and weight < 300 pounds (< 136 kg)
  3. Have been diagnosed with Stage III or IV NSCLC
  4. Be prior to first line chemotherapy
  5. Planned first line chemotherapy regimen is platinum plus paclitaxel only or platinum plus docetaxel only
  6. If surgery is part of the cancer treatment, screening for this study should be conducted at least 4 weeks (28 days) after surgery
  7. Life expectancy of > 6 months
  8. ECOG score ≤ 1
  9. Serum creatinine ≤ 2.0 mg/dL
  10. MALES - age ≥ 30 years
  11. FEMALES - age ≥ 30 years and clinically confirmed as postmenopausal. Subjects must have undergone the onset of spontaneous or surgical menopause prior to the start of this study. Spontaneous menopause is defined as the natural cessation of ovarian function as indicated by being amenorrheic for at least 12 months. If the subject has been amenorrheic for >6 months but <12 months they must have a serum FSH concentration of ≥ 50 mIU/mL and an estradiol concentration of ≤ 25 pg/mL. Surgical menopause is defined as bilateral oophorectomy.
  12. MALES - Subjects must agree to use a double barrier method of contraception during the study and for 3 months after study completion. This may include the following: condom + spermicide or condom + oral hormonal contraception
  13. MALES - have a serum PSA of ≤ 4.0 ng/mL or a negative prostate biopsy (no prostate cancer) within 6 months of evaluation

Exclusion Criteria
  1. Have, in the judgment of the Investigator, a clinically significant concurrent illness or psychological, familial, sociological, geographical or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol
  2. Have ALT/SGOT or AST/SGPT above 1.5 times the upper limit of normal (ULN) without evidence of liver metastases and above 5 times the ULN in subjects with evidence of liver metastases
  3. Have alkaline phosphatase greater than 3 times ULN and/or total bilirubin levels above 2 mg/dL at baseline
  4. Have biologic agents or kinase inhibitors as part of their first line chemotherapy regimen including, but not limited to bevacizumab (Avastin), gefitinib (Iressa) and erlotinib (Tarceva)
  5. Cardiovascular: uncontrolled hypertension, congestive heart failure or angina
  6. Pulmonary: Stage 4 chronic obstructive pulmonary disease (COPD)
  7. Positive screen for Hepatitis B consisting of HBsAg (Hepatitis B Surface Antigen), unless subject was diagnosed > 10 years prior to enrollment and no evidence of active liver disease
  8. Positive screen for anti-HCV (Hepatitis C Antibody), hepatitis A antibody IgM, or HIV
  9. Currently taking testosterone, oxandrolone (Oxandrin), testosterone-like agents (such as dehydroepiandrosterone (DHEA), androstenedione, and other androgenic compounds, including herbals), or antiandrogens; previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day washout (if previous testosterone therapy was long term depot within the past 6 months, the site should contact the medical monitor for this study to determine appropriate washout period)
  10. Currently taking megestrol acetate (Megace), dronabinol (Marinol), medical marijuana (medical cannabis) or any prescription medication intended to increase appetite or treat unintentional weight loss (any such products must be discontinued prior to randomization).
  11. Have a baseline stair climb time ≥ 30 seconds (mean of two stair climbs)
  12. Have active cancer, other than NSCLC or non-melanoma carcinoma of the skin, within previous two years.

Download the Cleveland Clinic Cancer Clinical Trials App

clinical trials app logo

Stay up to date on Cleveland Clinic’s more than 200 active clinical trials for cancer patients. Our free Cancer Clinical Trials app is available for Apple and Android devices.

With this app, you can:

The app also includes contacts for patient resources, financial services information, support groups and treatment guides.

Cleveland Clinic Cancer Trials - Cleveland Clinic Innovations
Android app on Google Play

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).


Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2015 Cleveland Clinic. All rights reserved.